Attachments
Q3 2022 Initiator Ph Engelsk FINAL
Share price
-4.38%
Turnover
0.86 MSEK
Subscription
Calendar
| Est. time* | ||
| 2026-11-20 | 08:30 | Quarterly Report 2026-Q3 |
| 2026-08-21 | 08:30 | Quarterly Report 2026-Q2 |
| 2026-05-29 | N/A | Annual General meeting |
| 2026-05-08 | 08:30 | Quarterly Report 2026-Q1 |
| 2026-02-20 | 08:30 | Year-end Report 2025 |
| 2025-11-21 | - | Quarterly Report 2025-Q3 |
| 2025-08-22 | - | Quarterly Report 2025-Q2 |
| 2025-05-26 | - | Ex-date Ordinary Dividend INIT 0.00 SEK |
| 2025-05-23 | - | Annual General meeting |
| 2025-05-09 | - | Quarterly Report 2025-Q1 |
| 2025-02-28 | - | Year-end Report 2024 |
| 2024-11-29 | - | Quarterly Report 2024-Q3 |
| 2024-08-23 | - | Quarterly Report 2024-Q2 |
| 2024-05-27 | - | Ex-date Ordinary Dividend INIT 0.00 SEK |
| 2024-05-24 | - | Annual General meeting |
| 2024-05-10 | - | Quarterly Report 2024-Q1 |
| 2024-02-23 | - | Year-end Report 2023 |
| 2023-11-10 | - | Quarterly Report 2023-Q3 |
| 2023-08-25 | - | Quarterly Report 2023-Q2 |
| 2023-05-29 | - | Ex-date Ordinary Dividend INIT 0.00 SEK |
| 2023-05-26 | - | Annual General meeting |
| 2023-05-05 | - | Quarterly Report 2023-Q1 |
| 2023-02-17 | - | Year-end Report 2022 |
| 2022-11-04 | - | Quarterly Report 2022-Q3 |
| 2022-08-26 | - | Quarterly Report 2022-Q2 |
| 2022-05-23 | - | Ex-date Ordinary Dividend INIT 0.00 SEK |
| 2022-05-20 | - | Annual General meeting |
| 2022-05-06 | - | Quarterly Report 2022-Q1 |
| 2022-02-18 | - | Year-end Report 2021 |
| 2021-11-19 | - | Quarterly Report 2021-Q3 |
| 2021-08-20 | - | Quarterly Report 2021-Q2 |
| 2021-05-31 | - | Ex-date Ordinary Dividend INIT 0.00 SEK |
| 2021-05-28 | - | Annual General meeting |
| 2021-05-25 | - | Quarterly Report 2021-Q1 |
| 2021-05-11 | - | Extra General Meeting 2021 |
| 2021-02-19 | - | Year-end Report 2020 |
| 2020-11-20 | - | Quarterly Report 2020-Q3 |
| 2020-08-21 | - | Quarterly Report 2020-Q2 |
| 2020-05-25 | - | Ex-date Ordinary Dividend INIT 0.00 SEK |
| 2020-05-22 | - | Annual General meeting |
| 2020-05-22 | - | Quarterly Report 2020-Q1 |
| 2020-02-21 | - | Year-end Report 2019 |
| 2019-11-22 | - | Quarterly Report 2019-Q3 |
| 2019-08-23 | - | Quarterly Report 2019-Q2 |
| 2019-05-24 | - | Ex-date Ordinary Dividend INIT 0.00 SEK |
| 2019-05-23 | - | Annual General meeting |
| 2019-05-23 | - | Quarterly Report 2019-Q1 |
| 2019-02-22 | - | Year-end Report 2018 |
| 2018-11-23 | - | Quarterly Report 2018-Q3 |
| 2018-08-24 | - | Quarterly Report 2018-Q2 |
| 2018-05-28 | - | Ex-date Ordinary Dividend INIT 0.00 SEK |
| 2018-05-25 | - | Annual General meeting |
| 2018-05-25 | - | Quarterly Report 2018-Q1 |
| 2018-03-01 | - | Extra General Meeting 2017 |
| 2018-02-21 | - | Year-end Report 2017 |
| 2017-11-24 | - | Quarterly Report 2017-Q3 |
| 2017-08-24 | - | Quarterly Report 2017-Q2 |
| 2017-05-26 | - | Quarterly Report 2017-Q1 |
| 2017-05-17 | - | Ex-date Ordinary Dividend INIT 0.00 SEK |
| 2017-05-16 | - | Annual General meeting |
Description
| Country | Denmark |
|---|---|
| List | First North Stockholm |
| Sector | Health care |
| Industry | Biotechnology |
Interested in the company’s key figures?
Analyze the company in Börsdata!
Who owns the company?
Find all ownership data in Holdings!
Business highlights in Q3 2022
- On July 5th the Company announced the outcome of the fully guaranteeed rights issue of MSEK 41. Approximately 42.3% of the share issue was subscribed for, with the rest covered by underwriting commitments.
- On July 5th the Company announced that it had carried out a directed share issue of MSEK 2.5 at a share price of SEK 7.50 to a strategic advisor to the company.
- On July 22nd the Company announced that it had completed a share buy back program of 24,000 shares in connection with the long-term incentive program LTI2021.
- On September 21st the Company announced that the final study report from the Phase 1 study in the IPTN2021 program confirmed the statistically significant effects on pain measures that were reported after the first data read-out in May.
Business highlights after this reporting period
- On October 4th the Company announced the outcome of the LTI2022 incentive programs to management and leading employees and to board members.
- On November 4th the Company provided an update on its clinical programs.
Financial Highlights
| Third Quarter (2022-07-01 – 2022-09-30) |
| Net revenue were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -6,689 (-9,056) |
| Earnings per share was DKK –0.13 (-0.24) |
| Cash: TDKK 46,768 (41,394) |
| Solidity: 70% (92%) |
| First Nine Months (2022-01-01 – 2022-09-30) |
| Net revenues were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -35,263 (-15,792) |
| Earnings per share was DKK –0.68 (-0.51) |
Solidity: equity divided by assets.
The Board of Directors have decided that interim reports will be published in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/
For additional information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com
About Initiator Pharma
Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition.
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.